Cannabis Science Updates Progress For Its Phytocannabinoid Pharmaceutical Products To Help Reduce ARDS-Associated Deaths From Both The Avian And Swine Influenza Infections
10:08 AM ET 9/21/09 | BusinessWire
Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report progress for its phytocannabinoid pharmaceutical products to help reduce ARDS-associated deaths from both the Avian and Swine Influenza infections.
Cannabis Science, Inc. President & CEO Dr. Robert Melamede stated, "After discussing our pharmaceutical products and initiatives with the FDA, Cannabis Science has taken certain steps to meet this potentially urgent situation. Although there is much yet to be done, I am very optimistic that we have an opportunity to have our products available to help meet this challenge."
Dr. Melamede concludes with an outline of Cannabis Science corporate guidance on its FDA procedures: "There are a number of critical capabilities that must be assembled into a cohesive whole. The guiding principle of both our scientific and business operations is that, by using appropriate independent contractors that are experts in their fields, the whole is greater than the sum of its parts.
Most importantly, we want everyone to understand the efficient and effective corporate structure that we are creating with holistic principles in mind. We are assembling teams in all the necessary arenas required for our growth and success. We have an agreement with a successful organic producer to provide us with the raw material. We are establishing a genetic testing facility to insure the production of consistent botanical products, as required for FDA approval, using state of the art procedures. We have identified a CGMP compliant processor who will make an FDA approvable extract for further processing by another qualified and experienced manufacturer, who will produce the final commercial product after FDA approval.
Our compliance team of professionals will oversee all of these activities with their many years of FDA experience. We are extremely pleased with the history and quality of expertise of the team that we are bringing together to face the immediate urgent challenges. We again thank our investors for their confidence in providing us with the necessary resources for this revolutionary undertaking. We have a number of exciting new initiatives we plan to announce shortly and we feel honored to be commissioned to make this happen."
H1N1 Swine Flu:
According to the CDC (http://www.cdc.gov/flu/avian/) the Avian flu (H5N1) has a 63% mortality rate. Unfortunately, the Swine flu, while thus far causing death at a much lower rate than the Avian flu, appears to also result in death via a similar mechanism. The common cause of death with these strains is organ failure, especially as seen in the lungs with the development of Adult Respiratory Distress Syndrome (ARDS). ARDS is caused by an excess immune-generated inflammatory response that leads to apoptosis (cell death) and subsequently to organ failure. The Company's approach will mimic how the human body uses endocannabinoids (cannabinoids that occur naturally in the body) to regulate immune activity and cell survival, by regulating inflammatory biochemistry. Excessive inflammatory responses are associated with numerous disease states including autoimmune diseases, neurological imbalances, and cardiovascular disease. Phytocannabinoids provide a natural means to supplement illness-specific endocannabinoid deficiencies.
Cannabis Science H1N1 Swine Flu Formulation:
We now know that the endocannabinoid system plays a critical role in maintaining human health. The human body produces Endocannabinoids on demand when they are needed. They help restore homeostasis (biochemical balance). The Cannabis plant produces Phytocannabinoids. When the human body has endocannabinoid deficiencies, it cannot effectively restore the healthy biochemical state needed to counter a particular illness. Phytocannabinoids from the Cannabis plant can replace the deficient endocannabinoid activity in the human body to restore a health-promoting level of cannabinoid activity. Cannabis Science will test its pharmaceutical products with FDA guidance and oversight to determine if it will reduce ARDS-associated deaths from both the Avian and Swine influenza infections.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
SOURCE: Cannabis Science Inc.